


# Prevalence of hepatitis B virus and hepatitis C virus infection in patients with systemic lupus erythematosus: a systematic review and meta-analysis

## SUPPLEMENTARY MATERIALS



**Supplementary Figure 1: Subgroup analysis of the prevalence rate for HCV in SLE patients and controls.** Forest plot shows the prevalence rate for HCV in SLE patients and controls, OR, odds ratio; CI, confidence Interval.

**Supplementary Table 1: Sensitivity analysis of HBcAb positive rate in SLE patients by omitting each study at a time**

<b>Excluded Study</b>	<b>OR (95% CI)</b>	<b>I<sup>2</sup></b>	<b>P</b>
Wang F, et al. 2016	0.40 (0.31–0.50)	0%	0.56
Watanabe R, et al. 2014	0.29 (0.19–0.44)	50%	0.08
Ram M, et al. 2008	0.33 (0.23–0.49)	59%	0.03
Berkun Y, et al. 2009	0.33 (0.23–0.48)	59%	0.03
Lu CL, et al. 1997	0.32 (0.20–0.51)	60%	0.03
Wu CX, et al. 2015	0.29 (0.19–0.45)	54%	0.06
Qiu N, et al. 2001	0.31 (0.21–0.47)	60%	0.03

**Supplementary Table 2: Sensitivity analysis of HCV positive rate in SLE patients by omitting each study at a time**

<b>Excluded Study</b>	<b>OR (95% CI)</b>	<b>I<sup>2</sup></b>	<b>P</b>
Feng H, et al. 2006	2.84 (2.15–3.76)	25%	0.23
Mahroum N, et al. 2017	3.25 (2.02–5.25)	26%	0.22
Ramos-Casals M, et al. 2000	2.64 (1.98–3.51)	0%	0.54
Agmon-Levin N, et al. 2009	2.90 (2.20–3.82)	27%	0.21
Mercado U, et al. 2005	2.98 (2.26–3.93)	20%	0.27
Wang S, et al. 2016	3.20 (2.40–4.28)	2%	0.41
Berkun Y, et al. 2009	2.95 (2.24–3.88)	25%	0.23
Mowla K. and E. Hajjani, 2008	2.91 (2.21–3.84)	28%	0.20
Costa CA, et al. 2002	2.81 (2.10–3.75)	25%	0.24